Shares of Danaher Corp. DHR advanced 1.43% to $238.20 Monday, on what proved to be an all-around mixed trading session for ...

Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on ...

A companion diagnostic is a medical device, often an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. The ...

Immunoassay analyzers are used to identify and detect the concentration of specific substances in a sample, usually using an antibody as a reagent. These devices are used in hospitals and clinical ...

A line-up of experts across academia, pharma, and healthcare came together to discuss the impact and challenges of ...

Discover why Danaher is a strong investment choice with its wide moat business model, M&A strategy, and growth potential for ...

In a report released on January 2, Patrick B Donnelly from Citi maintained a Buy rating on Danaher (DHR – Research Report), with a price target ...

Modus Advisors LLC bought a new stake in Danaher Co. (NYSE:DHR – Free Report) in the fourth quarter, according to its most ...

Danaher Corp (DHR) stock saw a modest uptick, ending the day at $229.81 which represents a slight increase of $0.26 or 0.11% from the prior close of $229.55. The stock opened at $230.72 and touched a ...

The stock's rise snapped a three-day losing streak.

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 2025 beginning at 8:00 a.m. ET and lasting ...

Bioconjugation Market Bioconjugation Market Dublin, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The "Bioconjugation Market by Product ...